Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Harvey

Showing results (371-380 of 419) with videos related to

Pageof 42
Sort By:
Cancer Treatment Reports|February 1, 1979
Phase II trial of cyclophosphamide, hexamethylmelamine, adriamycin, and cis-dichlorodiammineplatinum(II) combination chemotherapy in advanced ovarian carcinomaR Kane, H Harvey, T Andrews, et al.
Scientific Reports|December 27, 2024
Inhibition of pterygium cell fibrosis by the Rho kinase inhibitorJiannong Dai, Naga Pradeep Rayana, Michael Peng, et al.
Anticancer Research|March 1, 1986
Hormone stimulation and chemotherapy in advanced prostate cancer: interim analysis of an ongoing randomized trialA Manni, R J Santen, A E Boucher, et al.
Archives of Disease in Childhood|August 22, 2024
Natural history of spinal cord compression stage AFMS3 in infants with achondroplasia: retrospective cohort studyMoira Shang-Mei Cheung, Alessandra Cocca, Charlotte H Harvey, et al.
BMC Psychiatry|October 16, 2004
Single photon emission computed tomography (SPECT) of anxiety disorders before and after treatment with citalopramPaul D Carey, James Warwick, Dana J H Niehaus, et al.
The Journal of Clinical Endocrinology and Metabolism|July 1, 1991
Specificity of low dose fadrozole hydrochloride (CGS 16949A) as an aromatase inhibitorR J Santen, L M Demers, J Lynch, et al.
The Journal of Urology|December 1, 1986
Androgen priming and response to chemotherapy in advanced prostatic cancerA Manni, R J Santen, A E Boucher, et al.
The Journal of Biological Chemistry|March 30, 2001
Cell cycle and biochemical effects of PD 0183812. A potent inhibitor of the cyclin D-dependent kinases CDK4 and CDK6D W Fry, D C Bedford, P H Harvey, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 12, 2001
A phase I dose-ranging trial of monthly infusions of zoledronic acid for the treatment of osteolytic bone metastasesJ R Berenson, R A Vescio, L S Rosen, et al.
Genetics|June 24, 2005
Brc1-mediated DNA repair and damage toleranceDaniel M Sheedy, Dora Dimitrova, Jessica K Rankin, et al.
Pageof 42

Showing results (371-380 of 419) with videos related to

Sort By:
Pageof 42
Cancer Treatment Reports|February 1, 1979
Phase II trial of cyclophosphamide, hexamethylmelamine, adriamycin, and cis-dichlorodiammineplatinum(II) combination chemotherapy in advanced ovarian carcinomaR Kane, H Harvey, T Andrews, et al.
Scientific Reports|December 27, 2024
Inhibition of pterygium cell fibrosis by the Rho kinase inhibitorJiannong Dai, Naga Pradeep Rayana, Michael Peng, et al.
Anticancer Research|March 1, 1986
Hormone stimulation and chemotherapy in advanced prostate cancer: interim analysis of an ongoing randomized trialA Manni, R J Santen, A E Boucher, et al.
Archives of Disease in Childhood|August 22, 2024
Natural history of spinal cord compression stage AFMS3 in infants with achondroplasia: retrospective cohort studyMoira Shang-Mei Cheung, Alessandra Cocca, Charlotte H Harvey, et al.
BMC Psychiatry|October 16, 2004
Single photon emission computed tomography (SPECT) of anxiety disorders before and after treatment with citalopramPaul D Carey, James Warwick, Dana J H Niehaus, et al.
The Journal of Clinical Endocrinology and Metabolism|July 1, 1991
Specificity of low dose fadrozole hydrochloride (CGS 16949A) as an aromatase inhibitorR J Santen, L M Demers, J Lynch, et al.
The Journal of Urology|December 1, 1986
Androgen priming and response to chemotherapy in advanced prostatic cancerA Manni, R J Santen, A E Boucher, et al.
The Journal of Biological Chemistry|March 30, 2001
Cell cycle and biochemical effects of PD 0183812. A potent inhibitor of the cyclin D-dependent kinases CDK4 and CDK6D W Fry, D C Bedford, P H Harvey, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 12, 2001
A phase I dose-ranging trial of monthly infusions of zoledronic acid for the treatment of osteolytic bone metastasesJ R Berenson, R A Vescio, L S Rosen, et al.
Genetics|June 24, 2005
Brc1-mediated DNA repair and damage toleranceDaniel M Sheedy, Dora Dimitrova, Jessica K Rankin, et al.
Pageof 42